312 results on '"Bertoli, Sarah"'
Search Results
2. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
3. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
4. Cost comparison of post-remission strategies in younger and older AML patients in France
5. Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
6. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
7. Vitamin C and D supplementation in acute myeloid leukemia
8. Overlapping features of therapy-related and de novo NPM1-mutated AML
9. MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations
10. When acute promyelocytic leukaemia changes its face in the peripheral blood
11. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
12. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
13. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
14. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
15. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
16. Genomic landscape of hyperleukocytic acute myeloid leukemia
17. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
18. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
19. A case of acute megakaryoblastic leukaemia following a mediastinal germ cell tumour
20. Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia
21. Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
22. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
23. PB1764: SEGMENTATION AND CLASSIFICATION OF BONE MARROW CELLS FROM MULTI-PRECISION NUMERIZATION OF BONE MARROW SMEARS (BMS) FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) USING AI TECHNIQUES
24. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites
25. STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia
26. Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy.
27. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
28. Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
29. Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
30. Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study
31. Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
32. Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience
33. Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
34. Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
35. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
36. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
37. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms.
38. Improved outcome for AML patients over the years 2000–2014
39. Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy
40. Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
41. Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia
42. Genomics of Hyperleukocytic Acute Myeloid Leukemia
43. Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries
44. Comparison of 60 or 90 mg/m2 of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics
45. Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations
46. MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations
47. Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia
48. Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study
49. CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
50. Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.